Premium
Urinary phytoestrogen excretion and prostate cancer risk in a nested case‐control study: The Multiethnic Cohort
Author(s) -
Park SongYi,
Wilkens Lynne R.,
Franke Adrian A.,
Le Marchand Loïc,
Kakazu Kerry K.,
Goodman Marc T.,
Murphy Suzanne P.,
Henderson Brian E.,
Kolonel Laurence N.
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.898.10
Subject(s) - daidzein , equol , medicine , prostate cancer , nested case control study , enterolactone , genistein , phytoestrogens , odds ratio , cohort , oncology , excretion , cancer , endocrinology , estrogen
Phytoestrogens are of special interest in prostate cancer research because populations in Asia with a high consumption of phytoestrogens have a lower incidence of the disease than comparable populations in Western countries. This case‐control study is nested within a multiethnic cohort in Hawaii and California. Analyses included 249 incidence prostate cancer cases and 404 matched controls for urinary daidzein, genistein, equol, and enterolactone. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) to account for the matching criteria as well as adjusted for covariates. The median excretion of daidzein was 0.173 nmol/mg creatinine in cases and 0.291 in controls (p = 0.01), and the median excretion of genistein was 0.048 in cases and 0.078 in controls (p = 0.05). An inverse association was seen for daidzein overall (OR for the highest vs. lowest quintile = 0.55, 95% CI = 0.31‐0.98, p for trend = 0.03) and for localized as well as advanced or high grade cancer and was suggested for each of the four ethnic groups examined. Urinary excretion of genistein, equol, and enterolactone was not significantly related to prostate cancer risk. Our findings suggest that high intake of phytoestrogens, as reflected by urinary excretion of daidzein, may be protective against prostate cancer. Grant support: P01 CA33619 and R37 CA54281.